RCS - Hutchmed China Ltd - HUTCHMED to Host Expert Call to discuss ITP

HUTCHMED (China)Announcement

21/08/2024 09:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240821:nRSU2410Ba&default-theme=true

RNS Number : 2410B  Hutchmed (China) Limited  21 August 2024

Press Release

 

HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia

 

Hong Kong, Shanghai & Florham Park, NJ - Wednesday, August 21, 2024:
HUTCHMED (China) Limited ("HUTCHMED (https://www.hutch-med.com/) ")
(Nasdaq/AIM:HCM; HKEX:13) today announces that it will host a physician expert
call with a professor and key opinion leader in immune thrombocytopenia
("ITP"), to discuss the treatment landscape of ITP via webcast on Wednesday,
August 28, 2024, at 7:00 p.m. HKT.

 

The event will be held in Chinese (Putonghua) and can be accessed via
www.hutch-med.com/event (https://www.hutch-med.com/event/) . Investors
interested in listening to a webcast should log on before the start time to
download any software required. The transcript of the event, including an
English translation, will be available shortly thereafter for approximately 90
days. This event is intended for investor audiences only.

 

ESLIM-01 is a Phase III trial of HUTCHMED's novel investigational drug
candidate sovleplenib in patients with primary ITP in China. The trial met all
its endpoints and results were published in The Lancet Haematology
(https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00139-X/abstract)
and orally presented at the European Hematology Association (EHA) Hybrid
Congress. HUTCHMED filed a New Drug Application in China in January 2024 for
sovleplenib.

 

About ITP

 

ITP is an autoimmune disorder characterized by immunologic destruction of
platelets and decreased platelet production. Patients with ITP are at
increased risk of excessive bleeding and bruising. 1  (#_edn1) ITP is also
associated with fatigue (reported in up to 39% of adults with ITP) and
impaired quality of life. 2  (#_edn2) (, 3  (#_edn3) , 4  (#_edn4) , 5 
(#_edn5) , 6  (#_edn6) ) The incidence of primary ITP in adults is 3.3/100,000
adults per year with a prevalence of 9.5 per 100,000 adults. 7  (#_edn7) Based
on this prevalence rate, approximately 110,000 patients are estimated to be
living with primary ITP in China, in addition to 56,000 patients in the US,
Germany, France, Italy, Spain, UK, and Japan. It has been estimated that as
many as 145,000 patients are living with chronic ITP in major pharmaceutical
markets excluding China. 8  (#_edn8)

 

About Sovleplenib

 

Sovleplenib is a novel, selective inhibitor of Syk for once daily oral
administration. Syk, a non-receptor tyrosine kinase, is a major component in
B-cell receptor and FcR signaling and is an established target for the
treatment of multiple subtypes of B-cell lymphomas and autoimmune disorders.
Sovleplenib is currently under clinical investigation and its safety and
efficacy have not been approved by any regulatory authority. HUTCHMED
currently retains all rights to sovleplenib worldwide.

 

In addition to ITP (NCT05029635
(https://www.clinicaltrials.gov/ct2/show/NCT05029635) ), sovleplenib is also
being studied in warm antibody autoimmune hemolytic anemia (NCT05535933
(https://clinicaltrials.gov/ct2/show/NCT05535933) ) and indolent non-Hodgkin's
lymphoma (NCT03779113 (https://clinicaltrials.gov/ct2/show/NCT03779113) ).

 

About HUTCHMED

 

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage,
biopharmaceutical company. It is committed to the discovery, global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. It has approximately
5,000 personnel across all its companies, at the center of which is a team of
about 1,800 in oncology/immunology. Since inception, HUTCHMED has focused on
bringing cancer drug candidates from in-house discovery to patients around the
world, with its first three medicines now marketed in China, the first of
which is also marketed in the US and Europe. For more information, please
visit: www.hutch‑med.com (https://www.hutch-med.com/) or follow us on
LinkedIn (https://www.linkedin.com/company/hutchmed/) .

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the U.S. Private Securities Litigation Reform
Act of 1995. These forward-looking statements reflect HUTCHMED's current
expectations regarding future events, including its expectations regarding the
therapeutic potential of sovleplenib for the treatment of patients with ITP
and the further development of sovleplenib in this and other indications.
Forward-looking statements involve risks and uncertainties. Such risks and
uncertainties include, among other things, assumptions regarding the timing
and outcome of clinical studies and the sufficiency of clinical data to
support an NDA submission of sovleplenib for the treatment of patients with
ITP or other indications in China or other jurisdictions, its potential to
gain approvals from regulatory authorities on an expedited basis or at all,
the efficacy and safety profile of sovleplenib, HUTCHMED's ability to fund,
implement and complete its further clinical development and commercialization
plans for sovleplenib and the timing of these events. Existing and prospective
investors are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. For further discussion of
these and other risks, see HUTCHMED's filings with the U.S. Securities and
Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM.
HUTCHMED undertakes no obligation to update or revise the information
contained in this press release, whether as a result of new information,
future events or circumstances or otherwise.

 

Medical Information

 

This press release contains information about products that may not be
available in all countries, or may be available under different trademarks,
for different indications, in different dosages, or in different strengths.
Nothing contained herein should be considered a solicitation, promotion or
advertisement for any prescription drugs including the ones under development.

 

CONTACTS
 Investor Enquiries                                                       +852 2121 8200 / ir@hutch-med.com (mailto:ir@hutch-med.com)

 Media Enquiries
 Ben Atwell / Alex Shaw, FTI Consulting                                   +44 20 3727 1030 / +44 7771 913 902 (Mobile) /
                                                                          +44 7779 545 055 (Mobile) / HUTCHMED@fticonsulting.com
                                                                          (mailto:HUTCHMED@fticonsulting.com)
 Zhou Yi, Brunswick                                                       +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
                                                                          (mailto:HUTCHMED@brunswickgroup.com)

 Nominated Advisor
 Atholl Tweedie / Freddy Crossley / Rupert Dearden, Panmure Liberum       +44 (20) 3100 2000

 

 1  (#_ednref1) Zufferey A, Kapur R, Semple JW. Pathogenesis and Therapeutic
Mechanisms in Immune Thrombocytopenia (ITP). J. Clin. Med. 2017, 6(2), 16.

 2  (#_ednref2) McMillan R, Bussel JB, et al. Self-reported health-related
quality of life in adults with chronic immune thrombocytopenic purpura. Am J
Hematol. 2008 Feb;83(2):150-4.

 3  (#_ednref3) Snyder CF, Mathias SD, Cella D, et al. Health-related quality
of life of immune thrombocytopenic purpura patients: results from a
web‑based survey. Curr Med Res Opin. 2008 Oct;24(10):2767-76.

 4  (#_ednref4) Doobaree IU, Nandigam R, Bennett D, et al. Thromboembolism in
adults with primary immune thrombocytopenia: a systematic literature review
and meta-analysis. Eur J Haematol. 2016 Oct;97(4):321-30.

 5  (#_ednref5) Sarpatwari A, Bennett D, Logie JW, et al. Thromboembolic
events among adult patients with primary immune thrombocytopenia in the United
Kingdom General Practice Research Database. Haematologica. 2010
Jul;95(7):1167-75.

 6  (#_ednref6) Sarpatwari A, Watson S, Erqou S, et al. Health-related
lifestyle in adults and children with primary immune thrombocytopenia (ITP).
Br J Haematol. 2010 Oct;151(2):189-91.

 7  (#_ednref7) Lambert MP, Gernsheimer TB. Clinical updates in adult immune
thrombocytopenia. Blood. 2017 May 25;129(21):2829-2835.

 8  (#_ednref8) Clarivate Landscape & Forecast for Immune Thrombocytopenic
Purpura, 2018.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUASNRSBUWURR